Comparison of effects of cyclophosphamide, Cytembena, and Ypenyl in the treatment of inoperable ovarian carcinoma.
D000179:Acrylates / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use; D001772:Blood Cell Count; D001792:Blood Platelets / Q000187:drug effects; D001966:Bromine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005998:Glycine / Q000627:therapeutic use*; D006400:Hematocrit; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012156:Reticulocytes / Q000187:drug effects; D013941:Thymine / Q000627:therapeutic use*
D000179:Acrylates; D000970:Antineoplastic Agents; D001565:Benzoates; D009588:Nitrogen Mustard Compounds; D003520:Cyclophosphamide; D013941:Thymine; D001966:Bromine; D005998:Glycine